Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

Last Updated: Monday, July 17, 2023

Results from a phase 3 trial of patients with hematologic cancers who underwent HSCT showed that, at 1 year, the adjusted GVHD-free, relapse-free survival among those who received GVHD prophylaxis with cyclophosphamide–tacrolimus–mycophenolate mofetil was higher at 52.7% (95% CI: 45.8 to 59.2) compared with standard tacrolimus–methotrexate prophylaxis (34.9%; 95% CI: 28.6 to 41.3).

The New England Journal of Medicine

Targeted Oncology

Acute GVHD responds quickly to itolizumab treatment in phase 1b trial

Transplantation and Cellular Therapy

Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease

Journal of Clinical Oncology

Naive T-cell depletion to prevent chronic graft-versus-host disease

Blood

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease

The ASCO Post

Abatacept for prophylaxis of acute graft-vs-host disease

Translation and Cellular Therapy

A phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease

Blood

Prevention of acute GVHD disease using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T-cells in vivo

Translation and Cellular Therapy

Impact of conditioning regimen and graft-versus-host disease prophylaxis on the outcome of haploidentical peripheral blood stem cell transplantation for high-risk severe aplastic anaemia in children and young adults

Journal of Clinical Oncology

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

2022 ASH Annual Meeting

A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antithymocyte Globulin or Post-Transplant Cyclophosphamide Following alloHCT

Graft-vs.-Host Disease Resource Center

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

Targeted Oncology

Acute GVHD responds quickly to itolizumab treatment in phase 1b trial

Transplantation and Cellular Therapy

Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease

Journal of Clinical Oncology

Naive T-cell depletion to prevent chronic graft-versus-host disease

Blood

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease

The ASCO Post

Abatacept for prophylaxis of acute graft-vs-host disease

Translation and Cellular Therapy

A phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease

Blood

Prevention of acute GVHD disease using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T-cells in vivo

Translation and Cellular Therapy

Impact of conditioning regimen and graft-versus-host disease prophylaxis on the outcome of haploidentical peripheral blood stem cell transplantation for high-risk severe aplastic anaemia in children and young adults

Journal of Clinical Oncology

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

2022 ASH Annual Meeting

A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antithymocyte Globulin or Post-Transplant Cyclophosphamide Following alloHCT

Management of Chronic Oral GVHD in Patient with High-Risk AML and Mixed Chimerism

Patient With History of Acute Steroid-Dependent Skin GVHD Develops Chronic GVHD: Part 2

Patient With History of Acute Steroid-Dependent Skin GVHD Develops Chronic GVHD: Part 1